How do Sprycel and Tasigna compare head-to-head for CML?
Sprycel (dasatinib) and Tasigna (nilotinib) are both second-generation tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia (CML) in chronic, accelerated, or blast phases. Neither is definitively "better" overall—efficacy is similar, with major molecular response (MMR) rates around 40-50% at 12 months and deep molecular response rates comparable in trials.[1][2] Choice depends on patient factors like side effect tolerance, ABL mutations, and response monitoring.
What do clinical trial data show on response rates?
In the DASISION trial, Sprycel achieved a 12-month MMR rate of 46% versus 28% for Gleevec (imatinib), with faster and deeper responses.[1] The ENESTnd trial for Tasigna showed 12-month MMR of 44-51% (depending on dose) versus 22% for imatinib.[2] Cross-trial comparisons are imperfect due to design differences, but real-world data suggest similar 5-year progression-free survival (around 85-90% for both).[3] Sprycel may edge out in faster MMR achievement; Tasigna in some T315I mutation cases.
Which has better tolerability and fewer side effects?
Tasigna often has a better safety profile for long-term use. Common issues:
- Sprycel: Higher rates of pleural effusion (20-30%), myelosuppression, and bleeding; more discontinuations due to toxicity (~10-15%).[1][4]
- Tasigna: More QT prolongation, hyperglycemia, and pancreatitis risk; lower pleural effusion but requires ECG monitoring and fasting dosing.[2][4]
Patients with cardiovascular risks may prefer Sprydel; those prone to lung issues, Tasigna. Switch rates are similar (~20-30% over 5 years).[3]
When do doctors choose one over the other?
Guidelines (NCCN, ELN) recommend either as first-line for chronic-phase CML, based on:
- Sprycel preference: Younger patients, faster response needed, or certain mutations (e.g., Y253H).
- Tasigna preference: Patients with diabetes risk, need for once/twice-daily convenience, or T315I mutations (Tasigna more active).[5]
Treatment-free remission trials (e.g., EURO-SKI) show similar eligibility (~50%) for both after 2+ years of deep response.[6]
| Metric | Sprycel | Tasigna |
|--------|---------|---------|
| Dosing | 100mg once daily | 300mg twice daily (fasting) |
| MMR at 12 mo. | 46% | 44-51% |
| Pleural Effusion | 28% | <5% |
| CV Risk | Lower QT issues | Higher QT prolongation |
| Cost (US, monthly) | ~$14,000 | ~$14,000[7] |
What about patents, generics, and future access?
Sprycel's key patents expired in 2024-2025, with generics launching soon (e.g., Teva approval Dec 2024).[8] Tasigna's exclusivity ends ~2028-2031, delaying generics.[8] This could make Sprycel cheaper first. Check DrugPatentWatch.com for latest expiry dates and challengers.
Sources:
[1] NEJM DASISION (2010)
[2] NEJM ENESTnd (2010)
[3] ASH real-world data (2018)
[4] FDA labels
[5] NCCN CML Guidelines v2.2024
[6] Lancet EURO-SKI (2017)
[7] GoodRx pricing (2024)
[8] DrugPatentWatch.com